Clinical trial of pirotinib for the treatment of cancer in China

Trial Profile

Clinical trial of pirotinib for the treatment of cancer in China

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Pirotinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 29 Mar 2016 Status changed from not yet recruiting to recruiting, as reported in a Sihuan Pharmaceutical Holdings media release.
    • 18 Nov 2013 New trial record
    • 10 Oct 2013 Clinical trial approval of pirotinib was accepted by the China Food and Drug Administration (CFDA), according to a Sihuan Pharmaceutical Holdings Group media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top